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II. Synthesis and characterization
II-I. Synthesis of a disaccharide intermediate (4)
(4.64 g, 6.9 mmol) dissolved in dry acetonitrile was added lithium bromide (3.03g, 34.9 mmol) and stirred at r.t. for 3 h. The reaction mixture was diluted with ethyl acetate and extracted with water, washed with brine solution, dried with Na 2 SO 4 and concentrated. The crude product was purified by flash column chromatography (hexane/EtOAc= 10:90) and pure 2-azidobromide (3.47g, 5.09 mmol) was co-evaporated with toluene two times, added 3.47 g of molecular sieves
and once more co-evaporated with toluene, dried under vacuum for 12 h. To the residue, added dry dichloromethane (51 mL) and stirred at r.t for 15 min. To the resulting solution was added iodine (2.6 g, 20.3 mmol) and the solution was stirred at r.t. for 1 h and then silver carbonate (2.8 g, 10.1 mmol) and benzyl alcohol (1.58 mL, 15.2 mmol) were added and stirred at r.t. for 16 h. The mixture was diluted with chloroform followed by celite filtration, organic layer was washed with Na 2 S 2 O 3 solution, NaHCO 3 solution, brine solution, and dried over Na2SO4. The residual product was purified by flash column chromatography (hexane/EtOAc=65:35) to give benzyl glycoside 8 (1.8 g, 61%) as a white powder.
1
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Benzyl (2,3:4,6-di-O-benzylidine-β-D-mannopyranosyl)-(1→4)-2-azido-2-deoxy-β-D-glucopyranoside (9). 9
To a solution of 8 (8.1 g, 11.46 mmol) in dry methanol (114 mL, 0.1 M) was added sodium methoxide (309 mg, 5.73 mmol) and the solution was stirred at r.t. for 12 h. Then the solution was neutralized with Dowex 50W-X8
[H + ] resin. After the filtration, the solution was concentrated and dried in a vaccum for 3 h. The residue dissolved in dry N,N-dimethylformamide (114 mL, 0.1 M) was added benzaldehyde dimethyl acetal (5.1 mL, 34.39 mmol) and (±)-10-camphorsulfonic acid (799 mg, 3.43 mmol) under nitrogen gas. The mixture was stirred at 70 o C under reduced pressure for 3 h and then added aq. NaHCO 3 slowly at r.t., and extracted with EtOAc. The organic phase was dried over Na 2 SO 4 and concentrated. The crude residue was purified by flash column chromatography (hexane/EtOAc=72:28) to give a diastereomeric mixture 9 (3.32 g, 45%) as a white powder. Characterization data of the pure endo-isomer isolated were listed as follows. 13 C NMR (125 MHz, CDCl 3 , 25°C, TMS): δ 128. 3, 126.2, 126.2, 104.7, 101.9, 100.7, 100.5, 81.2, 76.8, 76.7, 74.3, 73.8, 73.3, 71.7, 71.6, 68.7, 68.7, 65.7, 65.6, 61.2, 61 
10
To a solution of the diastereomixture 9 (3.32g, 5.23 mmol) in dry N,N-dimethyl formamide (52 mL, 0.1 M), added 50% sodium hydride (377 mg, 15.7 mmol) at -15 o C and stirred for 15 min. Then added benzyl bromide (1.86 mL, 15.7 mmol) and stirred for o.n., added aq. NaHCO 3 was slowly and extracted with EtOAc. The organic phase was washed with water, brine, dried (Na2SO4) and concentrated. The crude residue was purified by flash column chromatography to give diastereomeric mixture (hexane/EtOAc=85:15) to give a white powdery 10 as a diastereo-mixture (3.59 g, 84%). Characterization data of the pure endo-isomer isolated were listed as follows. 4, 128.3, 127.9, 127.7, 126.6, 126.1, 105.0, 101.6, 100.8, 98.5, 81.1, 79.8, 76.8, 76.4, 76.1, 75.0, 75.0, 74.6, 73.8, 73.8, 71.1, 71.1, 68.6, 68.6, 67.9, 67.9, 65.9, 65.4 ; see, 2, 127.7, 126.2, 101.9, 101.7, 100.5, 81.6, 79.1, 79.0, 77.6, 75.9, 75.9, 75.3, 75.3, 74.9, 73.9, 73.9, 71.0, 70.9, 70.9, 68.4, 68.3, 67.0, 65.8 8, 128.4, 128.2, 126.9, 102.3, 101.0, 100.6, 98.7, 81.7, 78.8, 77.7, 76.6, 76.6, 75.7, 75.4, 75.2, 75.1, 74.7, 74.1, 73.9, 71.9, 70.9, 70.9, 71.2, 69.9, 68.8, 68.5, 68.4, 68.3, 68.3, 68.2, 66.9, 65.9, 65.8, 62.8, 61.6, 61.6, 55.4, 20.9, 20.9 ; see, Figure 
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Benzyl [(3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl-(1→2)-
3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-(1→3)-2-O-benzyl-β-D-mannopyranosyl]-(1→4)-2-azido-2-deoxy-3,6-di-O-benzyl-β-D-glucopyranoside (12).
12
A solution of compound 11 (400 mg) in 12 mL (acetic acid: water: ethanol = 4:1:1) was stirred at 80 o C. After reaction completion confirmed by TLC, the reaction mixture was evaporated and the crude residue was purified by flash column chromatography on silica gel (hexane/EtOAc=40:60) to give diol 12 (300 mg, 80%). 3, 128.2, 127.7, 126.7, 100.9, 100.4, 100.4, 96.8, 81.3, 81.0, 79.1, 77.1, 75.7, 75.1, 75.0, 75.0, 74.9, 74.5, 74.1, 73.9, 73.9, 73.9, 71.4, 71.4, 70.9, 70.8, 70.2, 70.1, 70.1, 69.6, 69.1, 68.6, 68.3, 66.9, 66.3, 66.3, 65.8, 64.1, 63.3, 63.1, 62.7, 62.6, 62.0, 62.0, 55.5, 20.8, 20.8 4, 128.2, 128.2, 128.0, 126.5, 101.9, 100.5, 100.3, 100.3, 97.3, 96.8, 96.5, 81.0, 81.0, 78.8, 76.7, 74.9, 74.9, 74.8, 74.7, 74.6, 74.2, 74.0, 73.9, 73.9, 73.8, 73.2, 72.9, 71.9, 71.8, 71.6, 71.3, 71.1, 71.0, 71.0, 70.9, 70.6, 70.1, 70.1, 70.0, 69.3, 69.2, 69.2, 68.6, 68.4, 68.3, 67.6, 67.5, 67.4, 67.4, 66.9, 66.0, 65.9, 65.8, 62.2, 62.1, 62.1, 61.8, 61.7, 56.3, 56.1, 56.0, 55.7, 21.0, 20.8, 20.8 
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To a solution of compound 13 (381 mg, 143 μmol) in EtOAc (13.0 mL) was added zinc (3.5 g, 53.19 mmol), acetic acid (750 μL, 35.94 mmol) and the solution was stirred at r.t., for 1 h. The reaction mixture was filtered through celite and washed with EtOAc. To the filtrate, Ac2O (800 μL) was added and the resulting mixture were stirred at r.t., for 15 h. The reaction mixture was concentrated and co-evaporated with toluene. The residue (300 mg) was dissolved in MeOH (4 mL). To the resulting solution was added NaOMe (6.9 mg, 131 mmol) and the mixture was stirred at room temperature for 16 h. The reaction mixture was neutralized using 20% acetic acid and concentrated. The residue was dissolved in water, lyophilized, and then the crude product was purified by RP HPLC to give compound 14 (184 mg, 79%). 6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.7, 101.3, 101.0, 99.6, 99.4, 99.3, 99.0, 96.3, 79.4, 79.4, 78.3, 77.8, 76.5, 76.4, 75.6, 75.0, 74.6, 74.5, 74.0, 73.9, 73.5, 73.5, 73.4, 73.1, 73.0, 72.7, 71.5, 71.4, 71.4, 69.8, 69.7, 69.7, 69.4, 69.4, 69.0, 68.0, 67.9, 67.4, 67.1, 65.9, 65.1, 65.0, 61.4, 60.5, 60.5, 59.8, 59.7, 55.5, 55.4, 54.5, 22.5, 22.4, 22 
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Benzyl {(β-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-Dmannopyranosyl)-(1→3)-[(β-D-galactopyranosyl-(1→4)-2-acetimido-2-deoxy-β-D-glucopyranosyl-(1→2)-β-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy--β-D-glucopyranosyl)-(1→6)]-α-Dmannopyranosyl)-(1→6)-2-O-benzyl-β-D-mannopyranosyl}-(1→4)-2-acetamido-2-deoxy-3,6-di-Obenzyl-β-D-glucopyranoside (15).
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To a solution of compound 14 (3.7 mg, 2.2 μmol) in 110.2 μL of water (20 mM; theoretical concentration), 6, 128.5, 128.5, 128.4, 127.6, 102.8, 102.8, 102.6, 101.2, 101.0, 99.5, 99.4, 99.2, 98.9, 96.2, 79.4, 79.3, 78.2, 77.8, 77.6, 76.4, 76.3, 75.2, 74.6, 74.5, 74.4, 74.0, 73.9, 73.9, 73.5, 73.1, 73.0, 72.5, 71.4, 71.3, 70.9, 69.9, 69.9, 69.3, 68.4, 67.9, 67.8, 67.4, 67.0, 66.0, 65.1, 65.0, 61.4, 61.4, 60.9, 60.0, 59.9, 59.2, 59.2, 54.9, 54.7, 22.5, 22.5, 22. 
β-D-galactopyranosyl-(1→4)-2-acetimido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→3)-[(β-D-galactopyranosyl-(1→4)-2-acetimido-2-deoxy-β-D-glucopyranosyl-(1→2)-β-Dgalactopyranosyl-(1→4)-2-acetimido-2-deoxy--β-D-glucopyranosyl)-(1→6)]-α-D-mannopyranosyl)-(1→6)-β-D-mannopyranosyl-(1→4)-2-acetamido-deoxy-D-glucopyranose (16).
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To a solution of compound 15 (9.0 mg, 3.6 μmol) in 50% AcOH (aq.) (4.0 mL), added 20% Pd(OH) 2 /C (5 mg) and stirred for 4 h under H 2 atmosphere. The reaction mixture was filtered through a celite pad, the filtrate was concentrated and then the residue was dissolved in water and lyophilized. The crude product was purified on a Sephadex G15 column by elution with H 2 O. Fractions containing the product were pooled and lyophilized to
give the free decasaccharide 16 (7.3 mg, 95%) as white solid. 8, 102.8, 102.8, 101.4, 100.1, 99.3, 99.3, 97.0, 94.8, 90.4, 80.2, 79.6, 78.3, 76.4, 76.2, 75.2, 74.5, 72.4, 71.9, 70.9, 70.2, 70.1, 68.4, 67.4, 67.2, 65.5, 65.3, 65.3, 61.6, 61.6, 61.0, 60.0, 59.8, 54.9, 53.5, 23.3, 23.3, 22.5, 22. 3; see, Figure S20 . with DMF and DCM (3 mL, three times each), Fmoc-removal, coupling, and capping procedures as described above were carried out repeatedly. After completion of the synthesis, the glycopeptidyl-resin was treated with TFA:H2O:TIS (95.0:2.5:2.5) (2.0 mL) at r.t. for 2 h and the resin was filtered. The resin was washed twice with the same cocktail and the filtrates were combined and concentrated by streaming of nitrogen gas. The glycopeptides was precipitated by adding cold tert-butylmethylether, discarded the liquid which is separated after centrifugation and the residue obtained was dissolved in 50% aq. acetonitrile and lyophilized. Then, the residue was dissolved in methanol (5.0 mL) and the pH was adjusted to 12.8 using 1 N sodium hydroxide, stirred at r.t. for 2 h. The mixture was neutralized by an addition of 1 N acetic acid and evaporated. The crude material was purified by RP-HPLC to yield pure compound 3 (1.6 mg, 5.4% overall yield calculated from the resin employed, 9.6 µmole). HPLC profile and MALDI-TOFMS were shown in Figure S21 . To a solution of decasaccharide 16 (7.3 mg, 3.4 μmol) in H2O (1.0 mL) was added Et3N (43 μL, 305 μmol) and 2-chloro-1,3-dimethylimidazolinium chloride (DMC) (22 mg, 119 μmol). The solution was stirred at 0 0 C for 40 min, then the reaction mixture was purified directly by gel filtration on a Sephadex G10 column eluted with 0.5% aq. NH3. The fractions containing the product was evaporated in vacuo and the residue was lyophilized to afford crude decasaccharide oxazoline 2 (approximately 7.0 mg) as a white solid. According to the general method reported previously, S3 unstable oxazoline derivative 2 was used directly for the next step without further purification. To a solution of 2 μL of 6.5 mM AGP glycopeptide 3 in Milli Q H2O, was added 2.6 μL (3eq.) of 15 mM decasaccharide oxazoline 2 dissolved in 25 mM phosphate buffer (pH6.0) and mutant endo-M-N175Q (50 mU/mL), and the mixture was incubated at 30 0 C for 10 h to provide compound 1 in 20% yield estimated from the reverse-phase analytical HPLC. As shown in Figure 2A in the main text, trans-glycosylation of an oxazoline 2 to the acceptor 3 monitored by reverse-phase analytical HPLC indicated that the reaction becomes an optimal at around 10 h and longer incubation appears to reduce the yield of the product. HPLC profile of the isolated AGP glycopeptide 1 was shown in Figure 2B in the main text. The accurate concentration of compound 1 was defined on the basis of the results of amino acid analysis as summarized in Table S1 . A solution of synthetic AGP glycopeptide 1 (800 fmol/µL) prepared in 1:1 ratio of 0.1% formic acid aq. and acetonitrile was used to analyze its mass and fragments by infusion method using 4000Q-TRAP mass spectrometry and syringe pump with a flow of 5µL/min using 1mL syringe of a diameter of 2, 649.6, 1448.5, 1550.4, 1652.0, 1733.0, 1814.2, 1894.9, 1996.6, 2077 .6 as shown in Figure 3B in the main text.
MALDI-TOF MS
MALDI-TOFMS
The selected fragments of glycopeptide 1 with m/z 1629.200 as Q1 for an optimization of MRM parameters were of m/z 1550. 400, 366.200, 2077.600, 1996.600, 1894.900, 1814.200, 1733.000, 1652 .000, 1448.500 and 649.600 ( Figure 3B in the main text). Out of which, fragments of m/z 366. 200, 2077.600, 1996.000, 1550.400, 649 .000 showed better intensity in cps with an increasing order of almost 366.200 > 2077.600 > 1996.000 > Table S1 . Amino acid analysis of synthetic AGP glycopeptide 1. 
